Related Experiment Video
Updated: Feb 8, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
Adalimumab therapy in hepatitis B virus-negative polyarteritis nodosa: A case report
Chrong-Reen Wang1, Chao-Chun Yang
1Department of Internal Medicine Department of Dermatology, National Cheng Kung University Hospital, Tainan, Taiwan.
Introduction:
Polyarteritis nodosa (PAN) is a difficult-to-treat rheumatology disorder, and biologic agents have been used in such patients with a treatment failure or the disease relapse.
Case Presentation:
We report a 42-year-old male Han Chinese who received adalimumab (ADA) alone during his vasculitis relapse, manifesting with weight loss, ankle arthritis, testicular inflammation and new-onset hypertension. Under the ADA 40 mg biweekly subcutaneous injection, there were the disappearance of clinical activity and no disease flares with a follow-up period of 26 months.
Conclusion:
The clinical observation in this patient suggests a potential efficacy of ADA therapy in controlling the disease activity of PAN.
Related Concept Videos
Gene Therapy
What are Viruses?
Negative Regulator Molecules
Positive, Negative, and Zero Work
Data Reporting and Recording
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

